My Crossword Maker Logo
Powered by BrightSprout
Save Status:
or to save your progress. The page will not refresh.
Controls:
SPACEBAR SWITCHES TYPING DIRECTION
Answer Key:
Edit a Copy:
Make Your Own:
Crossword Word Search Worksheet
Rate This Puzzle:
Log in or sign up to rate this puzzle.

Top 20 Infectious Disease Test Manufacturers Puzzle:2018 Annual Reports Edition

If you need extra clues, contact Michael Farmer at [email protected].
Across
We're the QC troll under the bridge of infectious disease markets.
During 2018, all of our infectious disease business came from our big immunoassay systems. But our new rapid syndromic panel instrument will be hurting BioFire, Luminex, and Genmark by the end of 2019.
If our dating life stays happy, maybe we'll proprose marriage to Seegene in 2019.
An Italian poet once wrote: Where would we be, without Vitamin D?
We're the main reason Meridian had a crummy year.
At the end of the year our stock was trading at 95 times revenues. We have nothing to fear but gravity.
We're working hard to stay #2 in AST markets and our CEO is a deal-addict like Trump. If he'd just buy us a decent blood culture system, that would help.
We're a public company run like a family business (hint: not Bio-Rad, the other one).
We're a distant #3 in blood culture, a distant #3 in AST, and the boss just divested our anatomic pathology unit. I'm polishing my resume; he may sell us next.
Down
We're the only private company among the top 20. We make and import microbiology consumables, and we stay out of the instrumentation business. The boss has been doing this for 38 years. Maybe he wants to sell soon.
The house that Kodak built and J&J cast aside, We hired bankers for our IPO a year ago; still no IPO seems likely in 2019.
We're big and bad and rich. All parasites, fungi, and bacteria fear us. So why is Copan beating us?
If not for our TB test, our 2018 numbers would have looked grim. But we've got two great new instruments to show US labs in 2019, so it should be a good year.
Our CEO's speech at the JP Morgan conference could have been source material for a new country music song: "My heart got broke by a little machine named Solana."
Palmetto's syndromic panel non-coverage decision hurts us more than anyone else in 2019.
Our POC MDx business was up 162%, blood screening was up 9%, and HPV was up 8% in 2018.
Our flexible syndromic panels make us a prime acquisition target in 2019.
We're the fastest gun in the MRSA business, and the star of Danaher's diagnostic division.
We've got three new POC rapid panels for the world in 2019, and nearly 400 instruments averaging $110,000 in annual revenue. So why is our stock getting no respect?
If we don't come up with a faster instrument and a bigger menu, Hologic, Roche, BD, and Qiagen will be hard to beat in 2019.